AN2 THERAPEUTICS INC
ANTXNASDAQ🏆 #3706 by market capEarnings Nov 5US Equity
$4.71▲ $0.17 (+3.75%)
After hours · at closeTrack ANTX
Get earnings, price moves & breaking news on Telegram
24h▲ 3.8%
7d▲ 29.3%
14d▲ 30.9%
30d▼ 7.7%
ytd▲ 331.7%
1y▲ 261.9%
🏦Market Cap
$178M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $4.56 – $4.88
- 52-Week Range
- $1.00 – $7.19
- Volume (shares)
- 18,895
- Avg Volume (shares)
- —
- Shares Outstanding
- 37.7M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.07
- Dividend Yield
- —
- Dilution (1yr)
- +1.1%
AN2 THERAPEUTICS INC
ANTXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$38M▼ −30.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$30M▼ −39.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.2M▲ +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$20M▼ −$1M YoY
StockOtter · stockotter.spaceAbout AN2 THERAPEUTICS INC
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy4
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.